EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterizing TLR4 agonist EmT4™ as an anti- Mycobacterium tuberculosis vaccine adjuvant

Sasha E Larsen iD, Maham Rais, Valerie A Reese, Debora Ferede, Tiffany Pecor, Suhavi Kaur, Deepika Nag iD, Thomas Smytheman, Sean A Gray, Darrick Carter, Susan L Baldwin, Rhea N Coler

ImmunoHorizons · 2025

DOI: 10.1093/immhor/vlaf014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoHorizons, 2025. Verfasst von Sasha E Larsen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, United States. Hauptthemen laut MEDLINE: Tuberculosis Vaccines, Mycobacterium tuberculosis, Toll-Like Receptor 4, Lipid A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is again the deadliest infectious disease globally, and more efficacious vaccines are needed to reduce this mortality. Successful subunit TB vaccines need antigens and adjuvants that are immunogenic, inexpensive, and accessible. Here we evaluated the potential of synthetically produced Monophosphoryl lipid A (SyMLP), a TLR4-agonist, formulated in an oil-in-water emulsion (EmT4™) in combination with selected fusion proteins, to drive an effective vaccine-mediated immunogenic response in C57BL/6 mice against Mycobacterium tuberculosis (M.tb) HN878 and H37Rv challenge. We first observed that EmT4™ enhances activation of C57BL/6 bone-marrow derived macrophages and dendritic cells measured by CD40, CD86, and MHCII expression by flow cytometry. EmT4™ did not induce safety signals in a scaled tolerability study. In immunogenicity studies, mice immunized 3 times 3 weeks apart with ID93 antigen + EmT4™ produced a significantly higher magnitude of circulating proinflammatory cytokines and ID93-specific immunoglobulin G (IgG) antibodies pre- and post-challenge with M.tb than saline control animals. Ex vivo ID93 restimulated splenocytes and lung cells elicited significant polyfunctional CD4+ T-helper 1 responses. Importantly, ID93 + EmT4™ immunizations significantly reduced bacterial burden in C57BL/6 mice 4 weeks post-challenge. Interestingly, EmT4™ paired with a next generation protein fusion ID91 also afforded prophylactic protection against M.tb HN878 challenge in both young (6 to 8 wk) and aged (20 mo) immunocompromised Beige mice. These protection and immunogenicity findings suggest that synthetically derived EmT4™ adjuvant is not only suitable to help backfill the preclinical TB vaccine candidate pipeline but is also suitable for the needs of the global community.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis VaccinesMycobacterium tuberculosisToll-Like Receptor 4Lipid AAdjuvants, ImmunologicTuberculosisAdjuvants, VaccineAnimalsMice, Inbred C57BLMiceFemaleDendritic CellsMacrophagesAntibodies, BacterialCytokinesImmunoglobulin G

Stichwörter der Autor:innen

Mycobacterium tuberculosisTBadjuvantmouse modelvaccine

Substanzen

Tuberculosis VaccinesToll-Like Receptor 4Lipid AAdjuvants, Immunologicmonophosphoryl lipid AAdjuvants, VaccineTlr4 protein, mouseAntibodies, BacterialCytokinesImmunoglobulin G

Autor:innen und Institutionen

  • Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle Children's Hospital, Seattle, WA, United States.
  • PAI Life Sciences Inc, Seattle, WA, United States.
  • Department of Global Health, University of Washington, Seattle, WA, United States.
  • Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.

ORCID-Profile: Sasha E Larsen, Deepika Nag

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Larsen, S. E., Rais, M., Reese, V. A., Ferede, D., Pecor, T., Kaur, S., Nag, D., Smytheman, T., Gray, S. A., Carter, D., Baldwin, S. L., & Coler, R. N. (2025). Characterizing TLR4 agonist EmT4™ as an anti- Mycobacterium tuberculosis vaccine adjuvant. ImmunoHorizons. https://doi.org/10.1093/immhor/vlaf014

Vancouver

Larsen SE, Rais M, Reese VA, Ferede D, Pecor T, Kaur S, et al. Characterizing TLR4 agonist EmT4™ as an anti- Mycobacterium tuberculosis vaccine adjuvant. ImmunoHorizons. 2025. doi:10.1093/immhor/vlaf014

BibTeX
@article{Larsen2025,
  author = {Larsen, Sasha E and Rais, Maham and Reese, Valerie A and Ferede, Debora and Pecor, Tiffany and Kaur, Suhavi and Nag, Deepika and Smytheman, Thomas and Gray, Sean A and Carter, Darrick and Baldwin, Susan L and Coler, Rhea N},
  title = {Characterizing TLR4 agonist EmT4™ as an anti- Mycobacterium tuberculosis vaccine adjuvant},
  journal = {ImmunoHorizons},
  year = {2025},
  doi = {10.1093/immhor/vlaf014}
}
Kostenlos starten →